ACIP votes to expand recommendation for RSV vaccine Abrysvo, to include adults aged 50 to 59 at increased risk of disease – Pfizer

Pfizer Inc. announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of respiratory syncytial virus (RSV) vaccines approved for adults 50-59 years of age at increased risk of RSV-associated lower respiratory tract disease (LRTD). This includes Abrysvo (Respiratory Syncytial Virus Vaccine), which in October 2024, the FDA approved for the prevention of RSV-associated LRTD in adults aged 18 to 59 at increased risk of severe disease.

According to the CDC, between 15,000 – 20,000 RSV-associated hospitalizations occur annually in U.S. adults aged 50 – 59 years. The risk of hospitalization is highest among those adults with one or more underlying medical conditions such as obesity, cardiovascular disease, diabetes, chronic obstructive pulmonary disorder (COPD), asthma and other chronic or immunocompromising conditions. With respect to Abrysvo, ACIP stated: ACIP recommends adults 50–59 years of age who are at increased risk of severe RSV disease receive a single dose of RSV vaccine.

“With its vote to expand adult RSV vaccination recommendations, ACIP has taken an important step toward protecting individuals aged 50 to 59 who have underlying medical conditions that increase their risk for severe RSV illness,” said Alejandro Cane, Vice President, Vaccines and Antivirals U.S. Medical Lead, Pfizer. “We are proud that ABRYSVO has the broadest indication among RSV vaccines, covering older adults, adults 18 and older at heightened risk of severe disease, and pregnant women to help protect infants.”

The updated ACIP recommendation, which lowers the recommended age for RSV vaccination from 60 to 50 for high-risk adults, is pending final approval by the director of the CDC and the Department of Health and Human Services.